GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » Gross Profit

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Gross Profit : $885 Mil (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings Gross Profit?

Integra Lifesciences Holdings's gross profit for the three months ended in Dec. 2023 was $226 Mil. Integra Lifesciences Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $885 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Integra Lifesciences Holdings's gross profit for the three months ended in Dec. 2023 was $226 Mil. Integra Lifesciences Holdings's Revenue for the three months ended in Dec. 2023 was $397 Mil. Therefore, Integra Lifesciences Holdings's Gross Margin % for the quarter that ended in Dec. 2023 was 57.05%.

Integra Lifesciences Holdings had a gross margin of 57.05% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Integra Lifesciences Holdings was 64.81%. The lowest was 57.39%. And the median was 62.16%.


Integra Lifesciences Holdings Gross Profit Historical Data

The historical data trend for Integra Lifesciences Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Gross Profit Chart

Integra Lifesciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 952.88 851.03 944.64 970.31 884.74

Integra Lifesciences Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 250.09 232.87 207.03 218.35 226.49

Competitive Comparison of Integra Lifesciences Holdings's Gross Profit

For the Medical Devices subindustry, Integra Lifesciences Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Gross Profit falls into.



Integra Lifesciences Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Integra Lifesciences Holdings's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1541.573 - 656.838
=885

Integra Lifesciences Holdings's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=397.039 - 170.546
=226

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $885 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Integra Lifesciences Holdings's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=226 / 397.039
=57.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Integra Lifesciences Holdings  (NAS:IART) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Integra Lifesciences Holdings had a gross margin of 57.05% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Integra Lifesciences Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Executives
Chantal Veillon-berteloot officer: EVP & CHRO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook officer: SVP, Fin & PAO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight officer: EVP & CFO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz officer: Corp VP, Gen Counsel & Sec C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De director, officer: President & CEO C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen officer: Executive VP & President, CSS 1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh officer: Exec VP & PRES, International 1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli officer: Chief Human Resources Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy director 14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman officer: CVP, CHIEF FINANCIAL OFFICER C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p. 10 percent owner 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini officer: President & COO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig director, officer: President and CEO 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Headlines

From GuruFocus

INTEGRA SHAREHOLDER ALERT

By PRNewswire 11-03-2023